JOP20210211A1 - طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر - Google Patents

طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر

Info

Publication number
JOP20210211A1
JOP20210211A1 JOP/2021/0211A JOP20210211A JOP20210211A1 JO P20210211 A1 JOP20210211 A1 JO P20210211A1 JO P20210211 A JOP20210211 A JO P20210211A JO P20210211 A1 JOP20210211 A1 JO P20210211A1
Authority
JO
Jordan
Prior art keywords
phosphorylated tau
peptide vaccine
tau peptide
safe administration
inducing
Prior art date
Application number
JOP/2021/0211A
Other languages
English (en)
Inventor
Bosch Maria Pihlgren
Nicolas Piot
Marco Donata De
Charlotte Sadaka
Saroj Raj Ghimire
Andreas Muhs
Andrea Pfeifer
Elizabeth Anne Ramsburg
Verhille Marija Vukicevic
Original Assignee
Janssen Pharmaceuticals Inc
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Ac Immune Sa filed Critical Janssen Pharmaceuticals Inc
Publication of JOP20210211A1 publication Critical patent/JOP20210211A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلّق الاختراع الحالي بطرق تحفيز أجسام مضادة تاو مضادة للفسفرة من دون التسبب بحدث ضائر شديد لدى البشر. تتضمن الطرق إعطاء المريض كمية فعالة من الجسيمات الشحمية التي تتضمن ناهض مستقبل شبيه بالتول 4 وفوسفو بيبتيد تاو المتواجدة على سطح الجسيم الشحمي.
JOP/2021/0211A 2019-02-08 2020-02-07 طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر JOP20210211A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802870P 2019-02-08 2019-02-08
PCT/US2020/017235 WO2020163730A2 (en) 2019-02-08 2020-02-07 Method of safe administration of phosphorylated tau peptide vaccine

Publications (1)

Publication Number Publication Date
JOP20210211A1 true JOP20210211A1 (ar) 2023-01-30

Family

ID=69780323

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0211A JOP20210211A1 (ar) 2019-02-08 2020-02-07 طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر

Country Status (15)

Country Link
US (2) US11684576B2 (ar)
EP (1) EP3920966A2 (ar)
JP (1) JP2022520060A (ar)
KR (1) KR20210125048A (ar)
CN (1) CN113710269A (ar)
AU (1) AU2020219804A1 (ar)
BR (1) BR112021014794A2 (ar)
CA (1) CA3129252A1 (ar)
EA (1) EA202192203A1 (ar)
IL (1) IL285163A (ar)
JO (1) JOP20210211A1 (ar)
MX (1) MX2021009508A (ar)
SG (1) SG11202108312PA (ar)
TW (1) TW202045204A (ar)
WO (1) WO2020163730A2 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11124552B2 (en) * 2017-10-25 2021-09-21 Ac Immune Sa Compositions of phosphorylated tau peptides and uses thereof
JP2022548780A (ja) * 2019-09-23 2022-11-21 マックォーリー・ユニバーシティ タウオパチーの治療
GB2600468A (en) * 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
CA3228878A1 (en) * 2021-08-12 2023-02-16 Andrea Pfeifer Liposomes containing phosphorylated tau peptides for inducing sustained immune responses
WO2023023332A1 (en) * 2021-08-20 2023-02-23 Thomas Jefferson University Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
EP0673418B1 (en) 1992-12-14 1998-05-06 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
MXPA03000316A (es) 2000-07-11 2004-04-05 Molecular Geriatrics Corp Reactivos y metodos para la identificacion de agentes de enlace.
GB0114719D0 (en) * 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
EP1474432A1 (en) 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
PL209696B1 (pl) * 2002-04-19 2011-10-31 Univ Toronto Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
WO2005080986A1 (en) 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
BRPI0619747B8 (pt) 2005-12-12 2021-05-25 Ac Immune Sa método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
SI2408807T1 (sl) 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
WO2012055933A1 (en) 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
US10400018B2 (en) 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
US10400034B2 (en) 2014-06-26 2019-09-03 Janssen Vaccines & Prevention, B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
JP6793134B2 (ja) 2015-06-05 2020-12-02 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
US11124552B2 (en) 2017-10-25 2021-09-21 Ac Immune Sa Compositions of phosphorylated tau peptides and uses thereof
JP2021502125A (ja) 2017-11-09 2021-01-28 ピンテオン セラピューティクス インコーポレイテッド ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物
BR112021021213A2 (pt) 2019-04-24 2021-12-21 Ac Immune Sa Administração heteróloga de vacinas de tau

Also Published As

Publication number Publication date
SG11202108312PA (en) 2021-08-30
EA202192203A1 (ru) 2021-10-20
US20200253873A1 (en) 2020-08-13
CN113710269A (zh) 2021-11-26
WO2020163730A3 (en) 2020-09-24
WO2020163730A2 (en) 2020-08-13
US11684576B2 (en) 2023-06-27
AU2020219804A1 (en) 2021-08-19
BR112021014794A2 (pt) 2021-10-05
MX2021009508A (es) 2021-09-08
CA3129252A1 (en) 2020-08-13
JP2022520060A (ja) 2022-03-28
IL285163A (en) 2021-09-30
TW202045204A (zh) 2020-12-16
US20230381108A1 (en) 2023-11-30
EP3920966A2 (en) 2021-12-15
KR20210125048A (ko) 2021-10-15

Similar Documents

Publication Publication Date Title
JOP20210211A1 (ar) طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر
US7569555B2 (en) Method for stimulating the immune, inflammatory or neuroprotective response
US20210340215A1 (en) T cell receptor constructs and uses thereof
JP6254251B2 (ja) がんの処置におけるサバイビンワクチンの有効性を向上させるための方法
Tseveleki et al. Mannan-conjugated myelin peptides prime non-pathogenic Th1 and Th17 cells and ameliorate experimental autoimmune encephalomyelitis
Adam et al. Probiotic Escherichia coli Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4‐dependent pathway
US20180162913A1 (en) Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
JOP20210284A1 (ar) الإعطاء غير المتجانس للقاحات تاو
ZA202101465B (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
JP2023055880A (ja) トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
Xue et al. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
Bell et al. An old problem with new solutions: strategies to improve vaccine efficacy in the elderly
Li et al. Establishment of nasal tolerance to heat shock protein-60 alleviates atherosclerosis by inducing TGF-β-dependent regulatory T cells
WO2014145839A3 (en) Liposomal vaccine adjuvants and methods of processing or using same
Tima et al. Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines
Okumura et al. The diacylglycerol kinase ζ inhibitor ASP1570 augments natural killer cell function
JP2018070629A (ja) がんの処置におけるサバイビンワクチンの有効性を向上させるための方法
WO2019089584A3 (en) Triblock peptide amphiphiles, micelles and methods of use
RU2785954C2 (ru) Конструкты т-клеточного рецептора и их применение
Bhatia et al. Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC)
MX2021014102A (es) Terapia de vacuna anti-abeta.
WO2023019241A3 (en) Liposomes containing phosphorylated tau peptides for inducing sustained immune responses
Katz et al. Etoposide Selectively Ablates Activated T